 |
|
|
| |
SILEN-C1: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic genotype-1 HCV infection
|
| |
| |
M.S. Sulkowski,1 C. Emanoil,2 T. Asselah,3 F.A. Caruntu,4 J. Lalezari,5 P. Ferenci,6
A. Streinu-Cercel,4 H. Fainboim,7 H. Tanno,8 L. Preotescu,4 B. Leggett,9 F. Bessone,10 S. Mauss,11 J.O. Stern,12 C. Häfner,13 Y. Datsenko,13 G. Nehmiz,13 W. Böcher,13 G. Steinmann13
On behalf of the SILEN-C1 study group
1Johns Hopkins University, Baltimore, MD, USA; 2"Dr. Victor Babes" Hospital for Infectious and Tropical Diseases, Bucharest, Romania; 3Hôpital Beaujon, Clichy Cedex, France, 4"Prof. Dr. Matei Bals" Institute of Infectious Diseases, Bucharest, Romania; 5Quest Clinical Research, San Francisco, CA, USA; 6Medical University of Vienna, Vienna, Austria; 7Hospital Francisco J. Muniz, Uspallata, Argentina; 8Hospital Provincial Del Centenario, Rosario, Argentina; 9Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia; 10Instituto CAICI, Rosario, Argentina; 11Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 12Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 13Boehringer Ingelheim Pharma, Biberach, Germany
|
| |
|
|
|
|
|
